CA2865202A1 - Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor - Google Patents

Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor Download PDF

Info

Publication number
CA2865202A1
CA2865202A1 CA2865202A CA2865202A CA2865202A1 CA 2865202 A1 CA2865202 A1 CA 2865202A1 CA 2865202 A CA2865202 A CA 2865202A CA 2865202 A CA2865202 A CA 2865202A CA 2865202 A1 CA2865202 A1 CA 2865202A1
Authority
CA
Canada
Prior art keywords
individual
e4orfl
adenovirus
protein
akt1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2865202A
Other languages
English (en)
French (fr)
Inventor
Nikhil Dhurandhar
Rashmi KRISHNAPURAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University
Original Assignee
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University filed Critical Louisiana State University
Publication of CA2865202A1 publication Critical patent/CA2865202A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2865202A 2012-01-20 2013-01-18 Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor Abandoned CA2865202A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261588959P 2012-01-20 2012-01-20
US61/588,959 2012-01-20
PCT/US2013/022126 WO2013109876A1 (en) 2012-01-20 2013-01-18 Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor

Publications (1)

Publication Number Publication Date
CA2865202A1 true CA2865202A1 (en) 2013-07-25

Family

ID=47664431

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2865202A Abandoned CA2865202A1 (en) 2012-01-20 2013-01-18 Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor

Country Status (7)

Country Link
US (1) US9433659B2 (https=)
EP (1) EP2804616B1 (https=)
JP (1) JP6175076B2 (https=)
AU (1) AU2013209580B2 (https=)
BR (1) BR112014017683A2 (https=)
CA (1) CA2865202A1 (https=)
WO (1) WO2013109876A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025080777A1 (en) * 2023-10-10 2025-04-17 Texas Tech University System Ad36e4orf1 peptide fragments as anti-diabetic agents
WO2025264791A1 (en) * 2024-06-18 2025-12-26 Texas Tech University System Recruiting the contribution of dlg1 to enhance insulin signaling pathway

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632013C (en) * 2005-11-30 2013-02-26 Wayne State University Adenovirus 36 e4 orf 1 gene and protein and their uses
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt

Also Published As

Publication number Publication date
EP2804616A1 (en) 2014-11-26
AU2013209580A1 (en) 2014-08-07
WO2013109876A1 (en) 2013-07-25
HK1204449A1 (en) 2015-11-20
BR112014017683A2 (pt) 2017-06-27
EP2804616B1 (en) 2018-07-18
JP6175076B2 (ja) 2017-08-02
JP2015505535A (ja) 2015-02-23
US9433659B2 (en) 2016-09-06
AU2013209580B2 (en) 2017-11-30
US20150038412A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
DK2968602T3 (en) SYNTHETIC METHYLMALONYL-COA MUTASE TRANSGEN TO TREAT MUT-CLASS METHYLMALONACIDEMIA (MMA)
US9486540B2 (en) Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders
US20250195610A1 (en) Methods for regulating free fatty acid flux using fat specific protein 27 (fsp27) compositions
WO2018089901A2 (en) Exosome delivery system
Zhong et al. Ciliary neurotrophic factor overexpression protects the heart against pathological remodelling in angiotensin II-infused mice
US20240384245A1 (en) Method for treating a disease
US9433659B2 (en) Enhanced glycemic control using Ad36E4orf1 and AKT1 inhibitor
JP5965397B2 (ja) 非アルコール性脂肪肝疾患の予防および治療のためのアデノウイルスａｄ３６ｅ４ｏｒｆ１タンパク質
HK1204449B (en) Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor
CN117899223A (zh) 以nup35基因和或以nup35蛋白作为作用靶点的物质的应用及组合物
CN117089548A (zh) 编码瘦素的核酸分子、组合物及应用
AU2020304701B2 (en) Compositions for use in the treatment of insulin deficiency conditions
US20100303790A1 (en) Use of biliverdin reductase (bvr) and bvr peptide fragments to treat coronary disorders
CN1948483B (zh) 抑制人RabJ基因表达的siRNA及其应用
AU2018301399A1 (en) Compositions and methods for treating myelin disorders
CA3114691A1 (en) Compositions and methods for the treatment of smooth muscle dysfunction
US12031134B2 (en) KLF11 siRNA for treatment of diabetes and obesity
US20200009227A1 (en) Compositions and methods of controlling expression of thermogenin (ucp-1) in skeletal muscles
JP6869530B2 (ja) ニューレグリン１α様活性を有するポリペプチド及び糖尿病治療用医薬組成物
CN119700940A (zh) LRP1-β链2AAAA短肽在治疗胰岛素抵抗和糖尿病中的应用
Ramos-Lobo et al. João AB Pedroso1, Daniella C. Buonfiglio1, Lais I. Cardinali1, Isadora C. Furigo1, Angela M.
CN103585629A (zh) 一种防治胰岛素抵抗及其相关疾病的新靶标

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180116

FZDE Discontinued

Effective date: 20210831